Radioimmunotherapy of prostate cancer

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 48, Issue 4, 2004, Pages 297-304

  Smith Jones, P M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Monoclonal antibody; Prostatic neoplasms; Radiopharmaceuticals

Indexed keywords

CAPROMAB PENDETIDE IN 111; COPPER 67; DOCETAXEL; GADOTERIC ACID; IODINE 131; LUTETIUM 177; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 7E11; MONOCLONAL ANTIBODY B.72.3; MONOCLONAL ANTIBODY CC49; MONOCLONAL ANTIBODY CC49 I 125; MONOCLONAL ANTIBODY CHL6; MONOCLONAL ANTIBODY CHL6 GADOTERIC ACID Y 90; MONOCLONAL ANTIBODY E4; MONOCLONAL ANTIBODY E4 I 131; MONOCLONAL ANTIBODY J591; MONOCLONAL ANTIBODY J591 BI 213; MONOCLONAL ANTIBODY J591 GADOTERIC ACID IN 111; MONOCLONAL ANTIBODY J591 GADOTERIC ACID LU 177; MONOCLONAL ANTIBODY J591 GADOTERIC ACID Y 90; MONOCLONAL ANTIBODY J591 I 131; MONOCLONAL ANTIBODY J591 IN 111; MONOCLONAL ANTIBODY J591 Y 90; MONOCLONAL ANTIBODY KC4; MONOCLONAL ANTIBODY KC4 Y 90; PACLITAXEL; PENTETIC ACID; RADIOPHARMACEUTICAL AGENT; RHENIUM 188; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 90; RADIOISOTOPE;

ANTIBODY AFFINITY; ANTIGEN EXPRESSION; BONE MARROW METASTASIS; BONE METASTASIS; CANCER SURVIVAL; CELL DEATH; CLINICAL TRIAL; DISSOCIATION CONSTANT; DOSIMETRY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STRUCTURE; HUMAN; ISOTOPE LABELING; METASTASIS POTENTIAL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE CANCER; PROTEIN TARGETING; RADIATION DOSE; RADIATION RESPONSE; RADIOIMMUNOTHERAPY; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR GROWTH; VASCULAR ENDOTHELIUM; MALE; METHODOLOGY; PROSTATE TUMOR;

ANTIBODIES, MONOCLONAL; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 15944376260     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Milenic DE, Brechbiel MW. Targeting of radio-isotopes for cancer therapy. Cancer Biol Ther 2004;3:361-70.
2. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002;43:693-713.
3. Knapp FF, Mirzadeh S. The continuing important role of radionuclide generator systems for nuclear medicine. Eur J Nucl Med 1994;21:1151-65.
4. Pentlow KS, Finn RD, Larson SM, Erdi YE, Beattie BJ, Humm JL. Quantitative imaging of yttrium-86 with PET. The occurrence and correction of anomalous apparent activity in high density regions. Clin Positron Imaging 2000;3:85-90.
5. Harwood SJ, Gibbons LK, Goldner PJ, Webster WB, Carroll RG. Outpatient radioimmunotherapy with Bexxar. Closed, clean air reservoir minimizes personnel radiation exposure. Cancer 2002;94(4 Suppl):1358-62.
6. Iznaga-Escobar N. Direct radiolabeling of monoclonal antibodies with rhenium-188 for radioimmunotherapy of solid tumors: a review of radiolabeling characteristics, quality control and in vitro stability studies. Appl Radiat Isot 2001;54:399-406.
7. Novak-Hofer I, Schubiger PA. Copper-67 as a therapeutic nuclide for radioimmunotherapy. Eur J Nucl Med Mol Imaging 2002;29: 821-30.
8. Schott ME, Schlom J, Siler K, Milenic DE, Eggensperger D, Colcher D et al. Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide labeled immunoconjugates. Cancer 1994;73(3 Suppl):993-8.
9. 188Re. Appl Radiat Isot 2001;55:89-96.
10. 177Lu process. Appl Radiat Isot 2000;53:421-5.
11. Kyker GC, Christopherson WM, Berg HF, Bruger M. Selective irradiation of lymph nodes by radiolutecium (Lu177). Cancer 1956;xx:489-98.
12. 177Lu-EDTMP: a potential therapeutic bone agent. Nucl Med Commun 1998;19:587-91.
13. 177Lu labelled polyaminophosphonates as potential agents for bone pain palliation. Nucl Med Commun 2002;23:67-74.
14. Hu F, Cutler CS, Hoffman T, Sieckman G, Volkert WA, Jurisson SS. Pm-149 DOTA bombesin analogs for potential radiotherapy: in vivo comparison with Sm-153 and Lu-177 labeled DO3A-amidebetaAla-BBN (7-14)NH(2). Nucl Med Biol 2002;29:423-30.
15. 177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003;30:417-22.
16. Meredith RF, Alvarez RD, Partridge EE, Khazaeli MB, Lin CY, Macey DJ et al. Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. Cancer Biother Radiopharm 2001;16:305-15.
17. 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma. Cancer Biother Radiopharm 2003; 18:525-33.
18. Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ et al. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol 2003;170(6 Pt 2):S84-8.
19. Sharkey RM, McBride WJ, Karacay H, Chang K, Griffiths GL, Hansen HJ et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res 2003;63:354-63.
20. Muller WA, Linzner U, Schaffer EH. Organ distribution studies of lutetium-177 in mouse. Int J Nucl Med Biol 1978;5:29-31.
21. Loccin MF, Desreux JF, Merciny E. Coordination of lanthanides by two polyamino polycarboxylic macrocycles: formation of highly stable lanthanide complexes. Inorg Chem 1986;25:2646-8.
22. Stimmel JB, Kull FC. Samarium-153 and lutetium-177 chelation properties of selected macrocyclic and acyclic ligands. Nucl Med Biol 1998;25:117-25.
23. Milenic DE, Garmestani K, Chappell LL, Dadachova E, Yordanov A, Ma D et al. In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. Nucl Med Biol 2002;29: 431-42.
24. 186Re. J Nucl Med 2004; 45:327-37.
25. Badalament RA, Burgers JK, Petty LR, Mojzisik CM, Berens A, Marsh W et al. Radioimmunoguided radical prostatectomy and lymphadenectomy. Cancer 1993;71:2268-75.
26. Meredith RF, Bueschen AJ, Khazaeli MB, Plott WE, Grizzle WE, Wheeler RH et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med 1994;35:1017-22.
27. 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer. Clin Cancer Res 1998;4:643-51.
28. 111In. Nucl Med Commun 1992;13:11-9.
29. O'Donnell RT, DeNardo SJ, Yuan A, Shen S, Richman CM, Lara PN et al. Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer. Clin Cancer Res 2001;7:1561-8.
30. DeNardo SJ, DeNardo GL, Yuan A, Richman CM, O'Donnell RT, Lara PN et al. Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N′,N",N"-tetra-acetic acid (DOTA) peptide versus 2IT-DOTA monoclonal antibody linkage for RIT. Clin Cancer Res 2003;9(10 Pt 2):3938S-44.
31. DeNardo GL, DeNardo SJ. Evaluation of a cathepsin cleavable peptide linked radioimmunoconjugate of a panadenocarcinoma MAb, m170, in mice and patients. Cancer Biother Radiopharm 2004;19:85-92.
32. O'Donnell RT, DeNardo SJ, Shi XB, Mirick GR, DeNardo GL, Kroger LA et al. L6 monoclonal antibody binds prostate cancer. Prostate 1998;37:91-7.
33. O'Donnell RT, DeNardo SJ, DeNardo GL, Miers L, Lamborn KR, Kukis DL et al. Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for PC3-tumored mice. Prostate 2000;44:187-92.
34. O'Donnell RT, DeNardo SJ, Miers LA, Lamborn KR, Kukis DL, DeNardo GL et al. Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6. Prostate 2002;50:27-37.
35. Abdel-Nabi H, Wright GL, Gulfo JV, Petrylak DP, Neal CE, Texter JE et al. Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer. Semin Urol 1992;10:45-54.
36. Essand M, Logdahl P, Nilsson S, Wartenberg M, Acker H, Carlsson J. Retention and processing of the monoclonal anti-prostate E4 antibody after binding to prostatic adenocarcinoma DU 145 cells. Cancer Immunol Immunother 1996;43:39-43.
37. Rydh A, Riklund Ahlstrom K, Widmark A, Johansson L, Nilsson S, Bergh A et al. Radioimmunoscintigraphy with a novel monoclonal antiprostate antibody (E4): an experimental study in nude mice. Cancer 1997;80(12 Suppl):2398-403.
38. Nilsson S, Essand M, Logdahl P, Larson A, Nordgren H, Juhlin C. E4, a new monoclonal antibody identifying a human prostatic cell surface antigen. Cancer Biother Radiopharm 1997;12:395-403.
39. Rydh A, Riklund-Ahlstrom K, Widmark A, Bergh A, Johansson L, Tavelin B et al. Radioimmunotherapy of DU-145 tumours in nude mice: a pilot study with E4, a novel monoclonal antibody against prostate cancer. Acta Oncol 1999;38:1075-9.
40. Rydh A, Riklund Ahlstrom K, Widmark A, Johansson L, Nilsson S, Bergh A et al. Radioimmunoscintigraphy using an anti-prostate monoclonal antibody (E4): a dosimetric evaluation. Urol Res 2001;29:216-20.
41. Holmes EH, Greene TG, Tino WT, Boynton AL, Aldape HC, Misrock SL et al. Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients. Prostate Suppl 1996;7:25-9.
42. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WDW. Expression of the prostate-specific membrane antigen. Cancer Res 1994;54: 1807-11.
43. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998;52:637-40.
44. Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995;62:552-8.
45. Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998;83:2259-69.
46. Wright GL, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D et al. Upregulation of prostate specific membrane antigen after androgen-depravation therapy. Urology 1996;48:326-34.
47. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192-8.
48. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WDW, Gaudin PB. Prostate specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999;5:2674-81.
49. Dumas F, Gala JL, Berteau F, Eschwege P, Pardis V, Lacour B et al. Molecular expression of PSMA mRNA and protein in primary renal tumors. Int Cancer 1999;80:799-803.
50. Gregorakis AK, Holmes EH, Murphy GP, Prostate-specific membrane antigen: current and future utility. Semin Urol Oncol 1998;16:2-12.
51. Tasch J, Gong M, Sadelain M, Heston WD. A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit Rev Immunol 2001;21:249-61.
52. Holmes EH. PSMA specific antibodies and their diagnostic and therapeutic use. Expert Opin Investig Drugs 2001;10:511-9.
53. 90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy. Cancer Biother Radiopharm 1999;14:99-111.
54. Lui H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V et al. Monoclonal antibodies to the extracellular domain of prostate specific membrane Antigen also react with tumor vascular endothelium. Cancer Res 1997;57:3629-34.
55. Lui H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V et al. Constitutive and antibody-induced internalization of prostate specific membrane antigen. Cancer Res 1998;58:4055-60.
56. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 2003;44:610-7.
57. Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 2003;30:667-76.
58. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. Cancer Res 2000;60:5237-43.
59. 213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res 2000;60:6095-100.
60. Vallabhajosula S, Smith-Jones PM, Navarro V, Goldsmith SJ, Bander NH. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice. Prostate 2004;58:145-55.
61. 90Y-hu-J591 mAb specific to PSMA: radioimmunotherapy (RIT) studies in nude mice with prostate cancer LNCaP tumor. Eur J Nucl Med 2000;8:951.
62. Smith-Jones; PM, St Omer S, Navarro V, Bander NH, Goldsmith SJ, Vallabhajosula S. Comparative biodistributions of In-111-DOTA-J591 and Lu-177-DOTA-J591: Ramifications for Y-90 dosimetry. J Nucl Med 2001;42(5 suppl):1021.
63. Goldsmith SJ, Kostakoglu L, Vallabhajosula S, Smith-Jones PM, Bremer S, Spangler T et al. Evaluation of anti-PSMA antibody, I-131 J591, in the treatment of prostate cancer. J Nucl Med 2000;41(5 Suppl):315.
64. Vallabhajosula S, Kuji I, Kostakoglu L, Smith-Jones PM, Zoe H, Bander NH et al. Radiolabeled humanized monoclonal antibodies to PSMA: phase I dose escalation studies with In-111-DOTA-hu-J591. J Nucl Med 2001;42 (5 Suppl):458.
65. Morris MJ, Pandit-Taskar N, Divgi C, Warren N, Nacca A, Smith-Jones P et al. Pilot trial of anti-PSMA antibody J591 for prostate cancer. Proc Am Soc Clin Oncol 2003;22:407.